Skip Navigation Links
Skip Navigation Links
Skip Navigation Links
Over Active Bladder –Quality of Life Implications
OAB is a clinical syndrome defined as urgency with or without urge incontinence usually with frequency and nocturia. It is a common problem: one... Read More
Over Active Bladder –Quality of Life Implications
OAB is a clinical syndrome charectarized by urgency, frequency, nocturia and incontinence usually.  This syndrome affects  greatly the quality of life.

OAB is a clinical syndrome defined as urgency with or without urge incontinence usually with frequency and nocturia. It is a common problem: one European survey of 16776 people aged 40 or older found an overall prevalence of over active bladder symptoms were frequency (85 per cent), urgency (54 per cent) and urge incontinence (36 per cent).

The overall prevalence of OAB is similar in men and women but incontinence is more common and symptoms worsen sooner among women. prevalence increases differently with age from 9 per cent in women and 3 per cent in men aged 40-44, 31 and 42 per cent respectively at age 75 or older.

OAB adversely affects quality of life in about 30 per cent of people aged 40 or older in UK, with a significant impact on social and physical functioning, emotion and particularly mobility in women. There is also a significant detrimental effect on mood and quality of sleep .Urinary urgency is the symptom patients say is most troubling, with the greater impact on quality of life than incontinence, frequency or nocturia.

Overall the impact of OAB on quality of life reported by patients is comparable with that associated with diabetes.

Concordance issues in OAB
Despite the associated morbidity many patients do not take their medication as prescribed or discontinue treatment. In one randomized trial involving 348 patients with OAB (defined as detrusor instability), of the 256 who could be followed up, only 18 percent has persisted with anticholinergic drug treatment for at least 6 months
Three analyses of US medical claims databases found that few patient persist with treatment for a year ,even with newer modified – release formulations that are claimed to reduce adverse effects.

In one, 47 per cent of patients taken an anticholinergic drug had stopped treatment after 3 months and 82 per cent had stopped by the year's end ; the mean duration of treatment was 86 days.
The second analysis found that 88 per cent of patients stopped treatment within a year , mostly within 6 months and only 15 per cent of patient took at least 80 per cent of their prescribed medication .
In the third, the mean duration of treatment for first time users of anticholinergic drugs was 91 days with oxybutynin and 143 days with tolterodine.

Theses studies did not investigate the reasons for this early discontinuation of treatment but it is likely that lack of effectiveness and adverse effects are the most common causes.

Adherence to treatment could be improved by adopting a joint approach between patient and healthcare provider. To achieve this ,clinicians need to enquire about patients' beliefs and concerns about their condition and its treatment and give them autonomy in decision making .in turn, patients need to understand their condition and the options for treatment they should have realistic expectations of what can be achieved with drug treatment and of the nature and likely hood of adverse effects so they can agree suitable goals and they should be offered ongoing support .

Finally, treatment should deliver an improvement in symptoms without the penalty of intolerable adverse effects .

Adapted from wagg, A; Maffatt, J.; and spinks, J.eds.confidence through bladder control .the role of propverine – current thinking
1- Abrams p, cardozo L, fall M,et al.the standardization of terminology of lower urinary tract function : report from the standardization sub committee of the international continence society . neurourol urodynamics 2002;21:167-78

2- milsom 1 , Abrams P,cardozo L, et al . How widespread are the symptoms of an overactive bladder and how are they managed? A population- based prevalence study. BJU int 2001; 87:760-6.

3- Mcgrother CW, Donaldson MM,shaw C,etal storage symptoms of the bladder : prevalence incidence and need for services in the UK.BJU Int 2004;93:763-9.

4- Strew WF,van rooyen JB,cundiff Gw,etal prevalence and burden of overactive bladder in the united states world J urol  2003;20:327-36.

5- van der vaart CH , De Leeuw JR , Roovers JP, et al. the effect of urinary incontinence and over active bladder symptoms on quality of life in young women.BJU Int 2002;90:544-9.

6- coyne KS, Zhou Z thomptoms c.versi E.the impact of urinary urgency and frequency on health-related quality of life in overactive bladder : results from a national community survey.value health 2004;7:455-63.

7- Kelleher CJ,Cardozo LD, Khuller V,et al a medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compiliance. Br J Obstel Gynaecol 1997;104:988-93.

8- Mcghan wf.cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder .Am J manage care 2001;7:62-75

9- Noe L, sneeringer R, patel B, et al .the implications of poor meducation persistence with treatment for overactive bladder.manag care interface 2004:17:54-60.

10- Chui MA,Williamson T,Arciniegra J et al .patient persistency with medications for overactive bladder .value health 2004;7:366(abstract).

11-YU YF, Yu AP , Ahn J, et al. Medication treatment persistence of overactive bladder /urinary incontinence patients in a California Medicaid program and the benefit of their refill adherence on urinary tract infection .value health 2003;6:191.

12-Zhou Z, Barr C, Torigoe Y, et al. persistence of therapy with drugs for overactive bladder value health 2001;4:161(abstract)

13- Dowell J.Jones A, Snadden D .exploring medication use to seek concordance with non adherent' patients: a qualitative study. Brj Gen pract 2002;52:24-32.

Future of Alzheimer's therapy: What is the best approach?
A new comprehensive review assesses current clinical trials for Alzheimer's drugs and advises on the best therapeutic approach going forward.
A new blood test could help diagnose Alzheimer's
New research focuses on an accurate blood test for Alzheimer's disease. If scientists replicate the study's promising results, it may be a breakthrough.
Dementia: Gene study boosts search for treatment
Using an innovative analytical approach, researchers pinpointed genes that play an important role in the protein buildup associated with dementia.
Gun ownership and dementia: A growing concern
As the older population of the United States grows, the prevalence of dementia also rises. A new paper discusses dementia and gun ownership.
Lung disease may increase dementia risk
New research uncovers another potential risk factor for dementia and, more generally, for cognitive impairment, namely having a lung disease in midlife.
Alzheimer's may soon be treated with HIV drugs
For the first time, scientists show how the gene that produces brain toxicity in Alzheimer's is 'recombined' using the same enzyme found in HIV.
Men who eat lots of fruits and vegetables have less memory loss
Consumption of orange juice, certain vegetables, leafy greens, and berry fruits is tied to less memory loss in a large group of men followed for 26 years.
Could managing cholesterol prevent Alzheimer's?
The largest genetic study of Alzheimer's to date finds that this neurological disease shares some genetic risk factors with several cardiovascular conditions.
Alzheimer's vaccine draws closer
Building on more than a decade of scientific research, a recent paper brings us one step closer to developing a vaccine for Alzheimer's disease.
A simple type of daily meditation may alter the course of Alzheimer's
Simple mind-body practices altered potential cell aging and Alzheimer's biomarkers. The changes linked directly to improved cognition and other functions.
Parkinson's disease: Scientists find new target to destroy protein clumps
In Parkinson's disease, toxic protein clumps accumulate in the brain's motor region. A study shows how targeting an enzyme could prevent this.
How a key protein boosts memory, learning in the adult brain
New research reveals that a protein that helps make connections between neurons in the developing infant brain also strengthens them in the adult brain.
Alzheimer's: Artificial intelligence predicts onset
A deep learning algorithm trained to analyze brain scans accurately predicted who would develop Alzheimer's more than 6 years before diagnosis.
How coffee protects the brain
New research reveals what gives coffee its protective properties for brain health, and why it can help keep Alzheimer's and Parkinson's disease at bay.
Alzheimer's may be treated with diabetes drugs
New research suggests that targeting the brain's capillary cells with antidiabetes drugs may relieve Alzheimer's-related brain pathologies.
Loneliness tied to a higher risk of dementia
A 10-year study of 12,000 diverse older adults finds that loneliness, independently of social isolation, is tied to a 40 percent higher risk of dementia.
Eye scan may detect Alzheimer's disease in seconds
It may soon be possible to diagnose Alzheimer's in a matter of seconds using a noninvasive eye scanner that simply examines a person's retina.
The signs and symptoms of Parkinson's disease
Parkinson’s disease is a neurological condition that affects a person in many different ways. Tremor is a well-known symptom but not the only one. Find out more.
How does stress affect the brain?
Stress can affect every aspect of our mental and physical health. A new study now shows just how exposure to stress can impact memory and brain volume.
How you breathe may affect your memory
Do you tend to breathe more through your nose or through your mouth? Your answer may affect your ability to consolidate new memories.
Herpes may account for 50 percent of Alzheimer's cases
A large review suggests that the herpes virus may result in a heightened risk of senile dementia, and may account for numerous Alzheimer's diagnoses.
Alzheimer's: These psychiatric symptoms may be an early sign
A postmortem study of brain tissue tests and interviews of those close to the deceased ties some psychiatric symptoms to early Alzheimer's disease.
Keto diet may protect against cognitive decline
Our diets can influence the state of our health. Research in mice now suggests that one regimen — the ketogenic diet — may even prevent cognitive decline.
Antidepressants could stave off dementia
The findings of a new study suggest that some antidepressants may block the growth of toxic plaques in the brain, thus helping to treat dementia.
How do hearing and sight influence cognitive decline?
Hearing and sight loss are tied to faster cognitive decline, so does addressing these issues slow down cognitive deterioration? New studies investigate.
<December 2018>
Home | Partners | Products | Researches| Monthly Articles | Distribution| Marketing | Useful Links | Careers | Contact Us | Site Map
Site Developed By Netegypt © 2010 TCHERO. All Rights Reserved.